View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Josseline Jenssen
  • Josseline Jenssen

Infragreen Group Ltd: 3 directors

Three Directors at Infragreen Group Ltd bought 833,800 shares at between 0.355AUD and 0.390AUD. The significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors o...

 PRESS RELEASE

Press Release: Sanofi’s rilzabrutinib earns orphan drug designation in...

Press Release: Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease Sanofi’s rilzabrutinib earns orphan drug designation in Japan for IgG4-related disease Designation based on positive data from a phase 2 study of rilzabrutinib in IgG4-RDThird global orphan drug designation for rilzabrutinib in IgG4-RD, underpinning Sanofi’s commitment to rare immune-mediated diseases Paris, March 2, 2026 – The Ministry of Health, Labour and Welfare (MHLW) in Japan has granted orphan drug designation to rilzabrutinib, a novel, oral, reversible covalent Bruton’s tyrosine ...

 PRESS RELEASE

Communiqué de presse : Le rilzabrutinib de Sanofi obtient la désignati...

Communiqué de presse : Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin au Japon pour la maladie liée aux IgG4 Le rilzabrutinib de Sanofi obtient la désignation de médicament orphelin au Japon pour la maladie liée aux IgG4 La désignation s’appuie sur les données positives d’une étude de phase 2 sur le rilzabrutinib dans la maladie liée aux IgG4Il s’agit de la troisième désignation mondiale de médicament orphelin pour le rilzabrutinib dans le traitement de la maladie liée aux IgG4, soulignant l’engagement de Sanofi dans la lutte contre les maladies rares à médiation...

 PRESS RELEASE

Space42 and Viasat to Share Progress on Equatys at Mobile World Congre...

Space42 and Viasat to Share Progress on Equatys at Mobile World Congress Companies advance plans for global system architecture and shared infrastructure for Direct-to-Device and other Advanced Mobile Satellite Services BARCELONA, Spain, March 02, 2026 (GLOBE NEWSWIRE) -- , the UAE-based AI-powered SpaceTech company, and , a global leader in satellite communications, will discuss continued progress toward their planned direct-to-device (D2D) infrastructure and offer an early look at the priorities for Equatys, the companies' forthcoming joint entity, during a co-hosted program at Mobile...

Stijn Demeester
  • Stijn Demeester

ArcelorMittal/Key beneficiary of trade defence/BUY

We raise our estimates, increase our target price from €38 to €64 per share, and reiterate our BUY recommendation. ArcelorMittal is a key beneficiary of far-reaching EU trade defence measures, to come into force as of 2H26.

 PRESS RELEASE

Aktsiaselts Infortar own share acquisition transactions

Aktsiaselts Infortar own share acquisition transactions Aktsiaselts Infortar acquired its own shares on the Nasdaq Tallinn Stock Exchange during the period of 23 - 27 February 2026 as follows: DateAggregated volume (pcs)Weighted average price per day (EUR)23.02.202618245,000024.02.20260-25.02.202619346,746626.02.202623045,990927.02.202624745,9664 Aktsiaselts Infortar is acquiring its own shares based on the stock exchange announcement . The share buyback programme is managed by SEB Pank AS, which will buy back shares on behalf of Aktsiaselts Infortar. Summary data (daily volume and weigh...

 PRESS RELEASE

Solvac has taken note of the market reaction following the recent publ...

Solvac has taken note of the market reaction following the recent publication of Syensqo’s results and outlook Press releaseRegulated information Brussels, March 2, 2026, 7.00 am CET Solvac is closely monitoring the situation and is in close contact with Syensqo’s Board of Directors and management. Solvac is fully mobilised in its role as a long‑term reference shareholder and is acting alongside Syensqo to support the company through this phase. Solvac is a public limited company under Belgian law founded in 1983 and listed on the Euronext Brussels stock exchange under the ISIN code BE0...

Stijn Demeester
  • Stijn Demeester

Aperam/Earnings inflection ahead of EU trade action/BUY

We reiterate our BUY recommendation and raise our target price from €32 per share to €50. We see a clear, positive earnings trajectory for Aperam, backed by self-help and stringent EU trade defence measures as of mid-2026F.

 PRESS RELEASE

Aktsiaseltsi Infortar omaaktsiate omandamise tehingud

Aktsiaseltsi Infortar omaaktsiate omandamise tehingud Aktsiaselts Infortar on perioodil 23 - 27. veebruar 2026 omandanud Nasdaq Tallinna börsil omaaktsiaid alljärgnevalt: KuupäevKoondmaht (tk)Kaalutud keskmine päevahind (EUR)23.02.202618245,000024.02.20260-25.02.202619346,746626.02.202623045,990927.02.202624745,9664 Aktsiaselts Infortar omandab omaaktsiaid vastavalt 20. oktoobril 2025 avalikustatud teatele. Aktsiate tagasiostu täideviijaks ja korraldajaks on AS SEB Pank, kes teostab aktsiate tagasiostu Aktsiaseltsi Infortar nimel. Omandamiste koondandmed (omandatud aktsiate kogus ja kaalut...

 PRESS RELEASE

Solvac heeft kennisgenomen van de marktreactie op de recente publicati...

Solvac heeft kennisgenomen van de marktreactie op de recente publicatie van de resultaten en vooruitzichten van Syensqo PersberichtGereglementeerde informatie Brussel, 2 maart 2026 – 7u00 CET Solvac volgt de situatie met de grootste aandacht en onderhoudt nauwe contacten met de Raad van Bestuur en het management van Syensqo. Solvac is volledig gemobiliseerd in haar rol als referentieaandeelhouder op lange termijn en handelt samen met Syensqo om de onderneming in deze fase te begeleiden. Solvac is een naamloze vennootschap naar Belgisch recht opgericht in 1983 en genoteerd op Euronext B...

 PRESS RELEASE

Solvac prend acte de la réaction des marchés à la publication récente ...

Solvac prend acte de la réaction des marchés à la publication récente des résultats et des perspectives de Syensqo Communiqué de PresseInformation réglementée                     Bruxelles, le 2 mars 2026 – 7h00 CET Solvac suit la situation avec la plus grande attention et est en contact étroit avec le Conseil d’administration et le management de Syensqo. Solvac est pleinement mobilisée dans son rôle d’actionnaire de référence de long terme et agit aux côtés de Syensqo, afin d’accompagner l’entreprise dans cette phase. Solvac est une société anonyme de droit belge fondée en 1983 et ...

ABGSC Pulp & Paper Research ... (+3)
  • ABGSC Pulp & Paper Research
  • Henrik Bartnes
  • Martin Melbye

Generation Development Group Limited: 1 director

A director at Generation Development Group Limited maiden bought 30,756 shares at 4.578AUD and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors ov...

Moody's Ratings assigns A2 rating to Vicinity's Australian Medium Term...

Moody's Ratings (Moody's) has today assigned an A2 senior unsecured rating to the AUD500 million 10-year Australian Medium Term Notes (AMTNs) of Vicinity Centres RE Ltd, a subsidiary of Vicinity Centres (VCX). The notes mature on March 3, 2036.               IMPORTANT NOTICE: MOODY'S RATINGS AND P...

ABGSC Strategy Research ... (+2)
  • ABGSC Strategy Research
  • Bengt Jonassen

Austin Engineering Ltd: 2 directors

Two Directors at Austin Engineering Ltd bought 645,000 shares at between 0.195AUD and 0.200AUD. The significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors o...

ABGSC Healthcare Research ... (+2)
  • ABGSC Healthcare Research
  • Morten Larsen
ABGSC Capital Goods Research ... (+3)
  • ABGSC Capital Goods Research
  • Anders Idborg
  • Karl Bokvist
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch